These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24378322)

  • 21. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR; Barrett PH; Vicini P; Miller DB; Telford DE; Kleinstiver SJ; Huff MW
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1906-14. PubMed ID: 9848883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
    Korolenko TA; Tuzikov FV; Cherkanova MS; Johnston TP; Tuzikova NA; Loginova VM; Filjushina EE; Kaledin VI
    Can J Physiol Pharmacol; 2012 Feb; 90(2):141-53. PubMed ID: 22320860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia.
    Almeda-Valdes P; Cuevas-Ramos D; Mehta R; Muñoz-Hernandez L; Cruz-Bautista I; Perez-Mendez O; Tusie-Luna MT; Gomez-Perez FJ; Pajukanta P; Matikainen N; Taskinen MR; Aguilar-Salinas CA
    BMC Endocr Disord; 2014 Nov; 14():90. PubMed ID: 25425215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model.
    Funatsu T; Kakuta H; Takasu T; Noguchi M; Suzuki M; Miyata K
    Metabolism; 2003 May; 52(5):609-15. PubMed ID: 12759892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
    Wilcox LJ; Barrett PH; Huff MW
    J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Barrett PH; Dubreuil D; Roy M; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Sep; 43(9):1464-71. PubMed ID: 12235178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia.
    Björn Lundahl ; Leren TP; Ose L; Hamsten A; Karpe F
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1784-8. PubMed ID: 10894817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
    Funatsu T; Suzuki K; Goto M; Arai Y; Kakuta H; Tanaka H; Yasuda S; Ida M; Nishijima S; Miyata K
    Atherosclerosis; 2001 Jul; 157(1):107-15. PubMed ID: 11427209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
    Funatsu T; Kakuta H; Takasu T; Miyata K
    Eur J Pharmacol; 2002 Nov; 455(2-3):161-7. PubMed ID: 12445582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men.
    St-Pierre J; Lemieux I; Miller-Felix I; Prud'homme D; Bergeron J; Gaudet D; Nadeau A; Despres JP; Vohl MC
    Atherosclerosis; 2002 Feb; 160(2):317-24. PubMed ID: 11849654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.
    Musso G; Gambino R; Cassader M
    J Nutr Biochem; 2010 Sep; 21(9):834-40. PubMed ID: 19733470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C.
    Mirandola S; Osterreicher CH; Marcolongo M; Datz C; Aigner E; Schlabrakowski A; Realdon S; Gerotto M; Alberti A; Stickel F
    Liver Int; 2009 Apr; 29(4):557-65. PubMed ID: 19018985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.
    Westphal S; Wiens L; Güttler K; Dierkes J; Luley C
    Atherosclerosis; 2003 Dec; 171(2):369-77. PubMed ID: 14644409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
    Blanco-Colio LM; Martín-Ventura JL; Sol JM; Díaz C; Hernández G; Egido J
    J Am Coll Cardiol; 2004 Apr; 43(7):1188-94. PubMed ID: 15063428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
    Ledmyr H; McMahon AD; Ehrenborg E; Nielsen LB; Neville M; Lithell H; MacFarlane PW; Packard CJ; Karpe F;
    Circulation; 2004 May; 109(19):2279-84. PubMed ID: 15136504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
    Aggarwal D; West KL; Zern TL; Shrestha S; Vergara-Jimenez M; Fernandez ML
    BMC Cardiovasc Disord; 2005 Sep; 5():30. PubMed ID: 16188040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I; Brook JG; Wolfovitz E
    Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.
    Castro Cabezas M; de Bruin TW; de Valk HW; Shoulders CC; Jansen H; Willem Erkelens D
    J Clin Invest; 1993 Jul; 92(1):160-8. PubMed ID: 8100834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition.
    Phillips C; Mullan K; Owens D; Tomkin GH
    Atherosclerosis; 2006 Jul; 187(1):57-64. PubMed ID: 16183064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.